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Background: Ten to 15% of CF infants present with meconium ileus (MI), that
sometimes can lead to intestinal malformation. Serum immunoreactive trypsin (IRT)
levels may be normal and newborn screening (NBS) could be erroneously consid-
ered negative. In our CFNBS protocol newborn babies presenting problems with
meconium passage (delay in meconium emission − MD − included) undergo sweat
test also if IRT is negative
Aim: The aim of this study is to investigate the incidence of CF in neonates with
MI and MD to determine if infants with this last condition have to be submitted to
CF diagnostic test.
Patients and Method: A retrospective 5-year study examines neonates screened
in our Center that presented problems in meconium passage, with regard to IRT
values and CF diagnosis.
Results: In a 5-year period (2006–2010) we screened 172,185 newborns and
diagnosed 50 CF. Eigthy-two newborns were reported having some problems related
to meconium passage: 13 were referred as MI (group 1), 7 as intestinal atresia (IA)
(group 2), 62 as MD (group 3).
In group 1 8/13 had IRT positive, 6/13 were diagnosed as CF and one of them
had IRT normal value; 2 died without diagnosis. In group 2 6/7 had IRT negative,
2/7 had CF and one of them was IRT negative. In group 3 nobody out 62 had IRT
positive, nor positive sweat test.
Conclusion: In this series 12% of CF neonates presented with MI and/or IA,
and 2 of them were IRT negative conﬁrming that CF with MI and IA can have
negative NBS. Delay in meconium pass is therefore, asscociated neither with
positive screening nor with CF, suggesting that newborns with MD and IRT negative
don’t require further analysis for CF.
47 CFTR gene mutations and the risk for developing a pancreatic
cancer: is it only a consequence of chronic inﬂammation?
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Objectives: CFTR and other gene mutations (SPINK1, PRSS1) are associated with
chronic pancreatitis (CP) that has been described to increase the risk for pancreatic
cancer (PCa). Some author suggested that a CFTR gene mutation may increase the
risk also through mechanisms not related to CP. We report our data regarding the
occurrence of PCa in patients affected by CP and their relatives and a possible link
with genetic factors.
Methods: We studied, retrospectively, 111 consecutive young patients (56 F, mean
age at diagnosis 9.1±5.6 yrs, range 4 months-18 yrs) affected by recurrent pan-
creatitis of several etiologies, including Cystic Fibrosis. A 14-year-old patient,
initially investigated for suspected pancreatitis, died for a malignant pancreatic
cancer. Genetic analysis was obtained in most patients and showed mutations in
CFTR, SPINK1 and PRSS1 genes in 41.2% (28/68), 7% (4/57) and 5.2% (3/58) of
patients, respectively. A positive family history for PCa was identiﬁed in 5 patients
(4.5%): 2 CF patients (a ﬁrst- and a second-degree relative, respectively), two sisters
affected by idiopathic CP, a patient with biliary lithiasis and a patient in whom we
detected a mutation in the SPINK1 gene (a second-degree relative in all cases).
Conclusions: We detected a signiﬁcant percentage (4.5%) of family history for PCa
and a case of PCa. However, our data are not consistent to hypothesize the impact
of a speciﬁc gene mutation in the PCa pathogenesis. It is likely that different genes
may contribute to the onset of PCa by favourishing chronic inﬂammation of the
pancreas. Future larger studies are needed to clarify the role of several genes in the
development of PCa.
